Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation

References

• Phelan R, Arora M, Chen M. 2020 Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides. Biol Blood Marrow Transplant. 2020;26(8):e177–e182.
   PubMed Web of Science ®Google Scholar
• Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry. N Engl J Med. 2014;371(4):339–348. doi:10.1056/NEJMsa1311707
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2021;107(5):1045–1053. doi:10.3324/haematol.2021.279189
   Web of Science ®Google Scholar
• Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med. 1993;328(9):593–602. doi:10.1056/NEJM199303043280901
   PubMed Web of Science ®Google Scholar
• NMDP. How does a patient’s ethnic background affect matching?. 2022. https://bethematch.org/transplant-basics/matching-patients-with-donors/how-does-a-patients-ethnic-background-affect-matching/
   Google Scholar
• Anasetti C, Aversa F, Brunstein CG. Back to the future: mismatched unrelated donor, haploidentical related donor, or unrelated umbilical cord blood transplantation? Biol Blood Marrow Transplant. 2012;18(1 Suppl):S161–S165. doi:10.1016/j.bbmt.2011.11.004
   PubMed Web of Science ®Google Scholar
• Majhail NS, Nayyar S, Santibañez ME, et al. Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transplant. 2012;47(11):1385–1390. doi:10.1038/bmt.2011.214
   PubMed Web of Science ®Google Scholar
• Hong S, Majhail NS. Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics. Hematology Am Soc Hematol Educ Program. 2021;2021(1):275–280. doi:10.1182/hematology.2021000259
   PubMedGoogle Scholar
• Besse K, Maiers M, Confer D, et al. On modeling human leukocyte Antigen-Identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source. Biol Blood Marrow Transplant. 2016;22(3):410–417. doi:10.1016/j.bbmt.2015.09.012
   PubMedGoogle Scholar
• O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377–386. doi:10.1053/bbmt.2002.v8.pm12171484
   PubMed Web of Science ®Google Scholar
• Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89(10):3864–3872. doi:10.1182/blood.V89.10.3864
   PubMed Web of Science ®Google Scholar
• Fuchs EJ. HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide. Bone Marrow Transplant. 2015;50(Suppl 2):S31–S36. doi:10.1038/bmt.2015.92
   PubMedGoogle Scholar
• Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-Identical siblings. N Engl J Med. 1985;313(13):765–771. doi:10.1056/NEJM198509263131301
   PubMed Web of Science ®Google Scholar
• Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320(4):197–204. doi:10.1056/NEJM198901263200401
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of High-Risk acute leukemia with T-cell–depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186–1193. doi:10.1056/NEJM199810223391702
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, O'Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021;137(3):420–428. doi:10.1182/blood.2020007535
   PubMed Web of Science ®Google Scholar
• Walker T, Milford E, Chell J, et al. The national marrow donor program: improving access to hematopoietic cell transplantation. Clin Transpl. 2011;2011:55–62.
   Google Scholar
• Rocha V, Fatobene G, Niederwieser D, Transplantation ftBSoBM, Blood tWNf, Transplantation M. Increasing access to allogeneic hematopoietic cell transplant: an international perspective. Hematology Am Soc Hematol Educ Program. 2021;2021(1):264–274. doi:10.1182/hematology.2021000258
   PubMedGoogle Scholar
• Mehta RS, Saliba RM, Ghanem S, et al. Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 2022;28:395.e391–395.e311.
   Google Scholar
• Grunwald MR, Zhang M-J, Elmariah H, et al. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021;5(4):975–983. doi:10.1182/bloodadvances.2020003654
   PubMed Web of Science ®Google Scholar
• Gooptu M, Romee R, St Martin A, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138(3):273–282. doi:10.1182/blood.2021011281
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–1040. doi:10.1182/blood-2015–04–639831
   PubMed Web of Science ®Google Scholar
• Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10. doi:10.1016/j.bbmt.2015.09.001
   PubMed Web of Science ®Google Scholar
• McCurdy SR, Fuchs EJ. Selecting the best haploidentical donor. Semin Hematol. 2016;53(4):246–251. doi:10.1053/j.seminhematol.2016.08.001
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, McCurdy SR, Solomon SR, et al. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood. 2022;139(10):1452–1468. doi:10.1182/blood.2021013443
   PubMed Web of Science ®Google Scholar
• Cho BS, Min GJ, Park S, et al. Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: a prospective comparative study. Am J Hematol. 2021;96(1):98–109. doi:10.1002/ajh.25993
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi:10.1016/j.bbmt.2008.03.005
   PubMed Web of Science ®Google Scholar
• Mussetti A, Kanate AS, Wang T, et al. Haploidentical Vs. Matched unrelated donor transplants using post-transplant cyclophosphamide for lymphoma: a joint CIBMTR/EBMT study. Blood. 2021;138(Supplement 1):174–174. doi:10.1182/blood-2021–151197
   Google Scholar
• McCurdy SR, Radojcic V, Tsai H-L, et al. Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood. 2022;139(4):608–623. doi:10.1182/blood.2021013054
   PubMed Web of Science ®Google Scholar
• Ramdial JL, Clemente-Sevilla L, Soebbing D, et al. A phase II clinical trial of "off-the-Shelf" NK cells with allogeneic stem cell transplantation to decrease disease relapse in patients with High-Risk myeloid malignancies. Blood. 2022;140(Supplement 1):7484–7485. doi:10.1182/blood-2022–170663
   Google Scholar
• Ciurea SO, Kongtim P, Soebbing D, et al. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022;36(1):155–164. doi:10.1038/s41375–021–01349–4
   PubMed Web of Science ®Google Scholar
• Arruda LCM, Gaballa A, Uhlin M. Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis. Blood Adv. 2019;3(21):3436–3448. doi:10.1182/bloodadvances.2019000682
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Abid MB, Auletta JJ, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021;137(23):3291–3305. doi:10.1182/blood.2020009362
   PubMed Web of Science ®Google Scholar
• McAdams MJ, Hyder M, Dimitrova D, et al. Phase I/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-Haploidentical bone marrow transplantation. Blood. 2021;138(Supplement 1):101–101. doi:10.1182/blood-2021–146997
   Google Scholar
• Akahoshi Y, Kimura SI, Gomyo A, et al. Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: association with chronic graft-versus-host disease and survival outcome. Hematol Oncol. 2018;36(1):276–284. doi:10.1002/hon.2427
   PubMed Web of Science ®Google Scholar
• Ramirez PA, Brunstein C, Miller B, et al. Delayed platelet recovery after allogeneic peripheral blood, marrow and umbilical cord stem cell transplantation: risk factors and clinical outcomes. Blood. 2009;114(22):867–867. doi:10.1182/blood.V114.22.867.867
   Google Scholar
• Bacigalupo A, Socié G, Schrezenmeier H, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012;97(8):1142–1148. doi:10.3324/haematol.2011.054841
   PubMed Web of Science ®Google Scholar
• Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the histocompatibility and alternate stem cell source working committee of the international bone marrow transplant registry. J Clin Oncol. 2004;22(24):4872–4880. doi:10.1200/JCO.2004.02.189
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397–1400. doi:10.1182/blood-2007–03–081596
   PubMed Web of Science ®Google Scholar